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The ﬂatworm Schistosoma mansoni is a blood ﬂuke parasite that causes schistosomiasis, a debilitating disease that occurs
throughout the developing world. Current schistosomiasis control strategies are mainly based on chemotherapy, but many
researchersbelievethatthebestlong-termstrategytocontrolschistosomiasisisthroughimmunizationwithanantischistosomiasis
vaccinecombinedwithdrugtreatment.SeveralpapersonSchistosomamansonivaccineanddrugdevelopmenthavebeenpublished
inthepastfewyears,representinganimportantﬁeldofstudy.Theadventoftechnologiesthatallowlarge-scalestudiesofgenesand
proteinshad a remarkable impact on thescreening of new and potential vaccine candidates in schistosomiasis.In this postgenomic
scenario, bioinformatic technologies have emerged as important tools to mine transcriptomic, genomic, and proteomic databases.
These new perspectives are leading to a new round of rational vaccine development. Herein, we discuss diﬀerent strategies to
identify potential S. mansoni vaccine candidates using computational vaccinology.
1.Introduction
Schistosomiasis mainly occurs in developing countries and it
is the most important human helminth infection in terms of
global mortality. This parasitic disease aﬀects more than 200
million people worldwide causing more than 250,000 deaths
per year [1]. Furthermore, schistosomiasis causes up to 4.5
million DALY (disability adjusted life year) losses annually
[2]. Current schistosomiasis control strategies are mainly
based on chemotherapy but, in spite of decades of mass
treatment, the number of infected people remains constant
[3]. Extensive endemic areas and constant reinfection of in-
dividuals together with poor sanitary conditions in devel-
oping countries make drug treatment alone ineﬃcient [4].
Many consider that the best long-term strategy to control
schistosomiasis is through immunization with an antis-
chistosomiasis vaccine combined with drug treatment [5].
A vaccine that induces even a partial reduction in worm bur-
dens could considerably reduce pathology and limit parasite
transmission [6].
The advent of technologies that allowed large-scale stud-
ies of genes and proteins had a remarkable impact on the
screening of new and potential vaccine candidates of Schisto-
soma mansoni. Mass spectrometry- (MS-)based proteomics
[7–10], transcriptome [11], and genome [12]o fS. mansoni
oﬀered a vast repertoire of potential targets for vaccine and
drug therapies. Despite this possibility to generate informa-
tion about DNA and protein sequences, it remains an obsta-
cle how to select them and which molecules would have the
highest potential among thousands or hundreds of potential
candidates. In this postgenomic scenario, bioinformatic
technologies have emerged as important tools to mine tran-
scriptomic, genomic, and proteomic databases. These new
approaches have the potential to accelerate the identiﬁcation2 Journal of Biomedicine and Biotechnology
of new generation of vaccine candidates that may induce
greater protection than the previous schistosome antigens
studied to date [13, 14]. Speciﬁc algorithms allow the iden-
tiﬁcation of molecules containing transmembrane domains,
signal peptides, signal anchors, and other posttranslational
modiﬁcations that can be used as predictors of excretory-
secretory products or components exposed to the surface of
the S. mansoni tegument [9, 13]. Additionally, predicting the
peptides that bind to MHC class II molecules can eﬀectively
reduce the number of experiments required for identifying
helper T-cell epitopes and play an important role in rational
vaccine design [15].
The tegument is a dynamic host-interactive surface in-
volved in nutrition, immune evasion and modulation, excre-
tion, osmoregulation, sensory reception, and signal trans-
duction [16, 17]. Consequently, the tegument is considered
an important source of parasite antigens for the develop-
ment of a schistosome vaccine. Currently, the most prom-
ising schistosome vaccine candidates are located in the tegu-
ment [18], such as TSP-2 [19]a n dS m 2 9[ 20].
Throughout the next sections we will discuss and present
the recent studies, approaches, and bioinformatics tools that
have been used to search and validate new vaccine targets
present in the tegument of S. mansoni.
2. Bioinformatic Approaches and Tools
The sequencing of the S. mansoni transcriptome [11, 12]a n d
the development of proteomic and microarray technologies
have dramatically improved the possibilities for identifying
novel vaccine candidates [21, 22]. In the search for an
eﬀective schistosome vaccine, several available bioinformatic
tools can be helpful and a rational design of possible vaccines
has replaced the trial-and-error approach [23]. A ﬁrst step
for a rational vaccine design is the identiﬁcation of target
antigens. For Schistosoma, a potential vaccine should include
proteins that are preferentially surface exposed and/or se-
creted ones, expressed in the intramammalian host [11].
The genes sequences can be obtain at the GenBank database
(http://www.ncbi.nlm.nih.gov/genbank/), and at the site of
the whole schistosome genome sequencing project (http://
www.SchistoDB.org). The proteins can be identiﬁed by prot-
eomic analysis which has resulted in a remarkable under-
standing of the protein composition of the schistosome teg-
ument [7–10, 24, 25]. If necessary, the target sequence can
be translated using the Translate tool which allows the
translation of nucleotide (DNA/RNA) sequence to a protein
sequence (http://expasy.org/tools/dna.html). Based on their
amino acid sequences, topology prediction to conﬁrm the
presence of transmembrane helices can be performed us-
ing TMHMM server v. 2.0 (http://www.cbs.dtu.dk/services/
TMHMM-2.0/)o rSOSUI (http://bp.nuap.nagoya-u.ac.jp/
sosui/) and subcellular localization can be performed using
the WolfPSORT (http://wolfpsort.org/aboutWoLF PSORT
.html.en).Theidentiﬁcation ofdomains within proteins can,
therefore, provide insights into their function and some
databases are able to identify known functionally important
sequence motifs that may not be identiﬁed on the basis of
sequencehomologybyitself.Suchsearchescanbeperformed
using diﬀerent tools as Pfam (http://pfam.janelia.org, http://
pfam.sanger.ac.uk/search?tab=searchSequenceBlock), Inter-
Pro Scan which integrates search in PROSITE, Pfam,
PRINTS, and other family, and domain databases (http://
www.ebi.ac.uk/Tools/pfa/iprscan/)o rScanProsite that scans
a sequence against PROSITE or a pattern against the UniProt
Knowledgebase (Swiss-Prot and TrEMBL) (http://expasy
.org/tools/scanprosite/). The prediction of either HLA-pep-
tide binding or proteasomal processing of antigens can be
predict for databases like SYFPEITHI (http://www.syfpeithi
.de/Scripts/MHCServer.dll/EpitopePrediction.htm) epitope
prediction algorithm, which comprises more than 7000 pep-
tide known sequences binding class I and class II MHC
molecules [26]o rNetChop (http://www.cbs.dtu.dk/services/
NetChop/) server that has been trained on human data only,
and will therefore presumably have better performance for
prediction of the cleavage sites of the human proteasome.
However, since the proteasome structure is quite conserved,
we believe that the server is able to produce reliable
predictions for at least the other mammalian proteasomes
[27]. Primary structure analysis can be performed at Prot-
Param (http://expasy.org/tools/protparam.html)t o o lw h i c h
allows the computation of various physical and chemical
parameters for a given protein stored in Swiss-Prot or
TrEMBL or for a user entered sequence [28]. Post-trans-
lational modiﬁcation prediction as N-glycosylation, Ogly-
cosylation and signal peptide can be analyzed using the
NetNGlyc 1.0 (http://www.cbs.dtu.dk/services/NetNGlyc/),
YinOYang (http://www.cbs.dtu.dk/services/YinOYang/)a n d
SignalP (http://www.cbs.dtu.dk/services/SignalP/), respec-
tively (Figure 1).
3. Tegument ProteinsasVaccine Candidates
3.1. Tegument Surface Exposed Proteins. Schistosome mem-
brane-bound antigens have currently become frequent tar-
gets of vaccines studies. Upon publication of the transcrip-
tome data and its scrutiny for genes with functions that
would indicate their surface exposure and likely interaction
with the host immune system, a series of novel genes were
oﬀered as potential vaccine candidates based on their func-
tional classiﬁcation by Gene Ontology [11, 29]. The use of
bioinformatic programs to screen and select potential vac-
cinetargetsfromtheavailableS.mansonisequencedatabases,
such as transcriptomes, genome, and proteomics is an im-
portant strategy for the rational design of vaccines, allowing
thepredictionofantigensinsilico[30].Theseinsilicoanalysis
have lead to the selection of several schistosome vaccine
candidates by diﬀerent research groups and the protective
eﬀect of some tegument antigens that were already tested in
vivowill be further discussed in this section and summarized
in Tables 1 and 2.
In the context of searching for new protective tegument
proteins, in 2006 Cardoso et al. [51] identiﬁed 34 proteins
with membrane-bound protein motifs. At the same time
other researchers across the world published the proteomic
analysis of S. mansoni tegument [8, 9]. One of the ﬁrst
tegument proteins selected and studied, as a potentialJournal of Biomedicine and Biotechnology 3
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Figure 1: Most common methodology for investigation of potential vaccine candidates. Possible targets are predicted based on sequences
databases and proteomic analysis. Further bioinformatic studies provide detailed information about protein primary structure, topology,
subcellular localization, conserved domains, HLA-peptide binding, and posttranslational modiﬁcations.∗ [7–10].
Table 1: S. mansoni tegument surface exposed proteins evaluated as vaccine targets.
Candidate Vaccine type Immunologic
response
Humoral
response Eggs reduction Worms
reduction Bioinformatic tool Ref.
Sm-p80 DNA vaccine
(PcDNA) Th1a,b IgG, IgG2a
and IgG2b 84% 59% ND [31]
TSP-2 Recombinant
protein ND IgG, IgG1
and IgG2a
64% (liver)
65% (feces) 57% BLAST [19, 32]
Sm29 Recombinant
protein Th1a,b
IgG, IgG1
and IgG2a
anti-Sm29
60% (intestinal
eggs) 51%
BLAST, InterPro
Scan, SignalP 3.0,
SignalP Neural,
NetNGlyc 1.0,
WolfPSORT, SOSUI,
Compute pI/Mw tool,
GOR IV.
[20, 21]
ECL (200 Kda
protein) DNA vaccine ND IgG, IgG1 >
IgG2a ND 38.1% ND [33]
Sm 25 Peptide
vaccine ND IgG
No
signiﬁcative
diﬀerence with
control group
No
signiﬁcative
diﬀerence with
control group
ND [34, 35]
ND: not determined. Sm25 were tested in mice and rats, all the others antigens were tested in mice.
schistosome vaccine, was the schistosome membrane-bound
protein Sm29 that was identiﬁed through membrane-bound
motif search using bioinformatic analysis [20, 51].
Sm29 is a membrane-bound protein with predicted
N-glycosylation and O-glycosylation sites, with unknown
function and no homolog outside the Schistosoma genus
[20, 21]. Recently, it was demonstrated that Sm29 is GPI-
anchored on the tegument surface of S. mansoni and
shaved oﬀ under phosphatidylinositol-speciﬁc phospholi-
pase C (PiPLC) treatment [10]. Sm29 as recombinant4 Journal of Biomedicine and Biotechnology
Table 2: Other S. mansoni tegument membrane proteins evaluated as vaccine targets.
Candidate Vaccine type Immunologic
response
Humoral
response Eggs reduction Worms
reduction Bioinformatic tool Ref.
Glutathione
peroxidase
DNA prime-
vaccinia virus
boost
ND ND ND 85% ND [36]
Sm21.7 Recombinant
protein ND ND ND 41–70% ND [37]
Cu/Zn
superoxide
dismutase
DNA vaccine ND ND ND 44–60% ND [36]
Filamin DNA vaccine Th1/Th2a,b IgG, IgG2a,
IgG2b, IgG1 ND 44–57% ND [38]
Sm ﬁmbrin +
Sm 21.7
Multivalent
DNA vaccine ND IgG
41.5% (liver)
55.6%
(intestine)
56% ND [39]
Sm-p80 DNA vaccine
(VR1020) Th1/Th17b IgG ND 47% ND [40]
Sm 23 DNA vaccine ND IgG ND 44% ND [41, 42]
Sm 21.7 DNA vaccine ND IgG
62% (liver)
67%
(intestine)
41.53% ND [43]
Fimbrin Recombinant
protein ND ND ND 39.4–41.6% Sequenase version
2.0, PC/GENE 15.0 [44]
Sm 22.6 Recombinant
protein Th1/Th2a,b IgG, IgG1
IgG2a ND 34.5% BLAST [45]
TSP-1 Recombinant
protein ND IgG, IgG1
and IgG2a
52% (liver)
69% (feces) 34% BLAST [19, 32]
Stomatin Like
Protein-2
Recombinant
protein Th1 IgG, IgG1 >
IgG2a
No
signiﬁcative
diﬀerence with
control group
30–32%
BLAST and PSI
BLAST, Pfam
SPFH/Band 7
domains, SignalP 3.0,
TMHMM, CSS-Palm,
MitoProt program,
Compute pI/Mw,
ClustalX 1.83,
TreeView program
[29]
Sm 20.8 DNA vaccine ND ND ND 28.5–30.8% ND [46]
Sm28GST
DNA vaccine
+plasmid
containing
IL-18
Th1a IgG∗
29.6% (liver)
27.5%
(intestine)
22.6% ND [47]
Dif 5 DNA vaccine ND ND ND 22%
BLASTX, Gene
Ontology
Consortium Website,
SMART, SignalP,
TMHMM, and bigPI
Predictor
[48]
SmIg Recombinant
protein Th1/Th2a,b IgG ND
No
signiﬁcative
diﬀerence with
control group
ExPASy (Expert
Protein Analysis
System), SignalP 3.0,
SOSUI, NetNGlyc 1.0,
YinOYang, BLAST,
INterPro Scan
[49]
Sm21.6 Recombinant
protein Th1/Th2b IgG, IgG1 >
IgG2 ND
No
signiﬁcative
diﬀerence with
control group
BLAST, Pfam
program, Syfpeith,
Expasy, Compute
pI/Mw tool, SignalP
3.0, YinOYang,
TMHMM
[50]
ND: not determined; ∗no diﬀerences when compared with the group containing just the plasmid with Sm28. aAntibody, bcytokines. All antigens were tested
in mice.Journal of Biomedicine and Biotechnology 5
vaccine induced a Th1 type of immune response in rSm29-
immunized mice, 50% reduction in liver granuloma, 60%
reduction in intestinal eggs, and 51% reduction in adult
worms [20].
Another group of proteins that are exposed on the teg-
ument surface, hence potential vaccine candidates, are the
integral membrane proteins tetraspanins TSP-1 and TSP-2
[19]. Tetraspanins cross the cell membrane four times and
play multiple roles in mammalian cell signaling, such as in-
teractions between immune eﬀector cells and their ligands
[32]. Vaccination of mice with these recombinant proteins
resulted in 57% reduction in worm burden and 34% reduc-
tion in liver eggs for rTSP-1 and 64% reduction in worm
burden and 52% reduction in liver eggs for rTSP-2 [19]. As
mentioned before, the current most promising schistosome
vaccine candidates are located in the tegument [18], such as
TSP-2 [19]a n dS m 2 9[ 20].
The calcium-dependent, neutral cysteine-protease (cal-
pain) was previously puriﬁed from S. mansoni [52]a n d
reported to be excreted/secreted [53] and present on the
tegument surface [10]. The large subunit of calpain (Sm-
p80) was tested as recombinant vaccine which provided a
29–39% reduction in worm burden in immunized mice
challenged with S. mansoni [54]. This antigen (Sm-p80) was
also evaluated in diﬀerent protocols of immunization, such
as DNA vaccine with Sm-p80 solely (39% of protection),
combined with IL-2 (57% of protection), or associated with
IL-12 (45% of protection) [55]. The authors attribute these
results to the pivotal role of calpain on surface membrane
biogenesis of schistosomes, as well as in the immune
evasion process [55]. Other recent publications of this group
reported higher levels of protection by Sm-p80 DNA-based
v a c c i n e s ,5 9 %r e d u c t i o ni nw o r mb u r d e ni nm i c e ,d e c r e a s e
in egg production by 84%, and a predominant Th1 immune
response [31]. Mice prime-immunized with DNA vaccine
andboostedtwicewithrSm-p80reducedupto70%inworm
burden and decreased egg production by up to 75% with
an induction of a Th1 and Th17 cytokine proﬁles [31]. Sm-
p80 was also cloned in VR1020, an FDA-approved vector
for human use. Additionally, the protective eﬃcacy of this
vaccine formulation was tested in a murine model. Sm-
p80-VR1020 vaccine formulation was able to induce 47%
r e d u c t i o ni nw o r mb u r d e n[ 40].
A glycosylphosphatidylinositol (GPI-anchored) protein
with unknown function was initially identiﬁed in the teg-
ument [56, 57] and termed later 200kDa, Sm200, or ECL
[33, 58, 59]. Brindley et al. [60] had suggested the use of
this protein as immunogen to trigger the immune response
against S. mansoni [60]. Furthermore, the immune and
protective responses induced by immunization with plasmid
DNA (ECL-encoded) complexed with protamine sulphate
as adjuvant was evaluated. The protection elicited was
38.1% and the spectrum of the elicited immune response
induced by the vaccine formulation without protamine were
characterized by a high level of IgG (IgG1 > IgG2a)[ 33].
Sm200, like Sm29, was released from the tegument surface
by an enzymatic shaving conﬁrming its tegument surface
localization [10].
Sm25, a major antigen on the tegument surface of S.
mansoni, is a 25kDa N-glycosylated glycoprotein that was
previously reported to be palmitoylated [34]. Recently, it was
demonstrated that Sm25 is a GPI-anchored protein on the
tegument surface [10]. Diﬀerently from previous tegument
surface antigens reported above that engendered substantial
levelsofprotectionasschistosomiasis vaccinecandidates, the
studies using rSm25 failed to protect mice against S. mansoni
cercariae challenges, despite the induction of speciﬁc anti-
Sm25 IgG [35].
3.2. Other Tegument Membrane-Bound Proteins. Some pro-
teins present in the tegument of S. mansoni,r e g a r d l e s so f
being exposed on the surface, when used as vaccines have
shown signiﬁcant levels of protection in mice. The most rel-
evant tegument proteins tested will be discussed below and
are summarized in Table 2. Proteomic analysis of S. mansoni
tegument [8, 9] provided the schistosome vaccinology ﬁeld
with promising candidates for vaccine design. Based on
these new proteomic databases, it was selected a protein
with unknown function that was termed SmIg because of
the presence of an immunoglobulin domain [22]. SmIg
tested as recombinant vaccine failed to induce worm burden
reduction, but immunized mice had signiﬁcant reduction of
liver granuloma area and ﬁbrosis content, showing a mixed
Th1/Th2 type of immune response [49]. Sm22.6 gene, en-
codingategumentprotein,wasﬁrstidentiﬁedinaS.mansoni
lung-stage cDNA library [45]. Further study has demon-
strated two EF-hand motifs present in this molecule [50].
Sm22.6, a speciﬁc schistosome lung-stage protein, was tested
as DNA and recombinant vaccine, but only the recombinant
form provided reduction on adult worm burden (34%) and
induced a mixed Th1/Th2 type of immune response [45].
A membrane-associated protein localized on the S. mansoni
adult worm, Sm21.6, was also tested as recombinant vaccine.
Sm21.6 showed 45% identity with Sm22.6, both possess EF-
hand antigen from the family of EF-hand containing parasite
proteins with sequence similarity to dynein light chain.
Bioinformatic analysis predicted Sm22.6 as a soluble protein
with neither signal peptide nor transmembrane domain,
and confocal microscopy analysis revealed this protein as
membrane-associated localized on the S. mansoni adult
worm [50]. Mouse immunization with rSm21.6 induced a
mixed Th1/Th2 cytokine proﬁle and no protection against
infection, but vaccination with rSm21.6 reduced by 28%
of liver granuloma numbers, 21% of granuloma area, and
34% of ﬁbrosis [50]. Further, a S. mansoni stomatin like
protein-2 (SmStoLP-2) was demonstrated to be localized on
the tegument and its recombinant form was also tested as
a schistosomiasis vaccine [29]. The function of stomatins is
still unknown. In erythrocytes, it may link stomatin or other
integral membrane proteins to the peripheral cytoskeleton,
playing a role in the regulation of ion channel conductance
or in the organization of sphingolipids and cholesterol-
rich lipid rafts [61]. Immunization with rSmStoLP-2 engen-
dered 32% reduction in adult worm burden and a Th1
predominant immune response [29]. Dif5 gene, a possible
homologue of human CD59/LY6, predicted to be GPI-
anchored on the S. mansoni tegument surface conferred 22%6 Journal of Biomedicine and Biotechnology
reductioninadultwormburdeninmiceimmunizedwiththe
Dif5 gene as DNA vaccine [48].
Sm21.7, a protein that was localized on the tegument of
S. mansoni by immunoﬂuorescence techniques, was tested
as recombinant [37]a n dD N A[ 43] vaccines. Similar to
Sm22.6, Sm21.7 has a motif strongly homologous to the EF
hand calcium binding domain; however, the change of the
invariant glycine to glutamine in the calcium binding loop,
makes this domain nonfunctional, as shown by the inability
of Sm21.7 to bind calcium [62]. Sm21.7 was identiﬁed in
cercariae, adults, and eggs whereas Sm22.6 and Sm20.8 were
expressed in adults [63]. Sm21.7 as recombinant and DNA
vaccines resulted in 41–70% and 41–53% reduction in the
number of adult worms, respectively, following challenge by
S. mansoni cercariae [37, 43]. Both forms of Sm21.7 vaccine
revealed a decrease in the number, size, and cellularity of
the granuloma in the liver of the vaccinated in comparison
with unvaccinated mice [37, 43]. Sm21.7 DNA vaccine was
also evaluated in association with the Sm ﬁmbrin gene as
DNAvaccine[39].ThisSm21.7/ﬁmbrinvaccineshowed56%
reduction in adult worm burden, 41% and 55% reduction
in liver and intestine eggs, respectively. Sm ﬁmbrin has
homology to actin binding proteins, presents a calcium-
binding site like in calmodulin molecules was localized on
the tegument of adult worms and its recombinant form
(solely) conferred 39.4–41.6% of protection in immunized
mice [44]. Sm23, an integral membrane protein detected
with antibodies in all stages of the parasite host forms,
engendered diﬀerent levels of protection (from 18% to 44%)
depending on the vaccine formulation [41, 42, 64]. Sm23 is a
23kDa integral membrane protein member of the “tetrasp-
anin” family, possessing four hydrophobic putative trans-
membrane domains, some of them involved in signal trans-
duction. Besides being an integral protein, Sm23 is addition-
ally linked to the membrane by a glycosylphosphatidylinosi-
tol anchor, but is not released from the surface after cleavage
with PiPLC [65]. This protein is expressed in all schistosome
lifestagesexaminedandinseveraltissues,includingtheadult
tegument[41].Sm20.8,anothertegumentprotein,isamem-
ber of a family of soluble tegument antigens that contain
EF-hand motifs, it interacts with dynein light chain and is
recognized as antigenic targets in protective antisera [46].
This Sm20.8 protein shows high homology to Sm21.7 and
Sm22.6 [46]. In immunization studies rSm20.8 conferred
30% reduction in adult worm burden in mice [46].
Antioxidant enzymes have been shown to be interesting
targets eliciting high levels of protection against S. mansoni
challenging. Moreover, their localization on the tegument
waspreviouslydemonstrated[66].Miceimmunizedwithcy-
tosolic Cu-Zn superoxide dismutase and glutathione peroxi-
dase as DNA vaccines showed reductions in worm burden at
levels 41–70% and 85%, respectively, depending on the anti-
genandthevaccineformulationusedinthestudies[36].The
association of Cu-Zn superoxide dismutase or glutathione
peroxidase with a partial sequence of the structural protein
ﬁlamin, as DNA vaccines, resulted in protections ranging
from 39% to 50% [38]. Another schistosome antioxidant
enzyme, glutathione S-transferase (Sm28GST), when associ-
ated with IL-18 as DNA vaccine resulted in 28% reduction in
e g gl a y i n ga n d2 3 %r e d u c t i o ni nw o r mb u r d e ni nm i c e[ 47]
a n du pt o5 9 %r e d u cti o ni nw o rmb u r d e ni nra t si m m u n i z e d
with a single dose of rSm28GST, using either aluminum
hydroxide or Bacillus Calmette-Gu´ erin as adjuvants [67].
Sm28GST was extensively explored as a potential antigen
against schistosomiasis in diﬀerent immunization protocols
and vaccine formulations [68–75]. These studies exploring
Sm28GST as vaccine candidate and its evaluation in human
clinical trials are revised in Capron et al. 2005 [76].
A strong evidence of the potentiality of S. mansoni teg-
ument-bound antigens as vaccine candidates was recently
demonstrated using an extract of tegument proteins from
lung-stage schistosomula named Smteg [77]. Smteg-immu-
nized mice showed a Th1 type of immune response associ-
ated with 48% reduction in worm burden, 65% reduction in
liver eggs, 60% reduction in fecal eggs, and 41% reduction in
liver granuloma [77].
4.Perspectives
Even though funding for vaccine development against schis-
tosomiasis has dropped signiﬁcantly, there is a common
understanding within the scientiﬁc community that long-
term eﬀective disease control will beneﬁt from the combina-
tion of vaccination and chemotherapy, plus sanitation and
public health control measures [78]. The current vaccine
candidates may prove not to be the most eﬀective, but it is
important to continue identifying new target antigens [14].
Consequently, the characterization and better understanding
of the S. mansoni tegument composition, coupled with new
bioinformatic approaches and tools will deﬁnitely initiate
a new era for the development of schistosome vaccines.
A recent publication identiﬁed several tegument-associated
proteins released through enzymatic shaving [10]. This work
presented a new repertoire of interesting and potential
vaccine candidates to be explored, such as annexin [79],
S. mansoni nucleotide pyrophosphatase/phosphodiesterase
type 5 (SmNPP-5) [80], and an amino acid transporter,
Schistosomepermease1(SPRM1)[81].Besidesthesesurface
exposed antigens, other potential tegument antigens to be
further evaluated are the ones related to uptake or transport
ofnutrients,drugs,andothermoleculesacrossthetegument,
such as aquaporins [82, 83]. Other candidates previously
identiﬁed as tegument proteins, although not tested as
vaccine, are the receptors such as the histamine receptors
SmGPR-1 [84] and SmGPR-2 [85]. The major challenge to
develop vaccines using deﬁned and single antigens is ﬁnding
molecules able to stimulate appropriate immune responses
that can lead to resistance. However, a strategy that could
accelerate the achievement of an eﬀective antischistosomiasis
vaccine would be the association of diﬀerent recombinant
antigensthatpreviouslyresultedinpartialprotectionoreven
the use of pools of antigens known as multivalent or mul-
tiepitope vaccines. This strategy was evaluated for some
researchers using associations of S. mansoni synthetic pep-
tides or even DNA-based vaccines but their approach did
not engender higher levels of protection when compared
to the use of a single antigen [39, 86]. This demonstrates
that no additive or synergistic eﬀects were obtained fromJournal of Biomedicine and Biotechnology 7
the diﬀerent antigens selected in those studies but it could
be related to the speciﬁc combination of antigens and/or the
type of immune response resulted from this association and
do not exclude the possibility of success using other parasite
antigens. Taken together, all proteins discussed here, and
manyothersidentiﬁedbybioinformatictools,couldimprove
the search for an eﬀective antischistosomiasis vaccine, and
consequently, disease control.
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